Oncology and Hematology - Prova Education

Episodes 33-48 of 92

Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
MinuteCE®
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
MinuteCE®
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
MinuteCE®
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
1.00 program credit
- Egbert Smit, MD
1.00 program credit
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
MinuteCE®
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
1.00 program credit
- Egbert Smit, MD
1.00 program credit
MinuteCE®
Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer
1.00 credit 10 episodes
- Nadia Harbeck, MD, PhD
- Egbert Smit, MD
- Susana Campos, MD, MPH
1.00 credit 10 episodes
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
MinuteCE®
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
MinuteCE®
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
CME/CE
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
0.25 credits
- Caitlin Costello, MD
- Sagar Lonial, MD, FACP
0.25 credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
0.25 credits
- Benjamin Levy, MD
- Alexander Spira, MD, PhD, FACP
0.25 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
0.25 credits
- Helena Yu, MD
0.25 credits
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
CME/CE
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
0.25 credits
- Caitlin Costello, MD
- Sagar Lonial, MD, FACP
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
0.50 credits
- Jyoti Patel, MD
- Pasi Antero Jänne, MD, PhD
0.50 credits
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
MinuteCE®
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
1.00 program credit
- Sagar Lonial, MD, FACP
- Caitlin Costello, MD
1.00 program credit
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
MinuteCE®
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
1.00 program credit
- Sagar Lonial, MD, FACP
- Caitlin Costello, MD
1.00 program credit
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
MinuteCE®
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
1.00 program credit
- Sagar Lonial, MD, FACP
- Caitlin Costello, MD
1.00 program credit
Clinical Challenges With Triple-Class or Penta-Refractory MM
Clinical Challenges With Triple-Class or Penta-Refractory MM
MinuteCE®
Clinical Challenges With Triple-Class or Penta-Refractory MM
1.00 program credit
- Sagar Lonial, MD, FACP
- Caitlin Costello, MD
1.00 program credit

3/6